Prospective economic evaluation alongside the non-invasive ventilation trial

Area of Science:

• Neonatal medicine
• Health economics
• Clinical trial analysis

Background:

• Nasal continuous positive pressure (nCPAP) and nasal intermittent positive pressure ventilation (NIPPV) are common respiratory support methods for infants.
• Previous randomized clinical trials have established the clinical equivalence of nCPAP and NIPPV.
• The economic implications of choosing between these two ventilation strategies require thorough investigation.

Purpose of the Study:

• To conduct a cost-effectiveness analysis comparing nCPAP and NIPPV.
• To evaluate the economic outcomes from both a third-party payer and a societal perspective.
• To determine if NIPPV offers economic advantages over nCPAP in infant respiratory support.

Main Methods:

• Utilized patient-level data from a previously reported randomized clinical trial.
• Performed a prospective economic evaluation from a third-party payer perspective for all patients.
• Conducted a subgroup analysis from a societal perspective with a defined time horizon.

Main Results:

• Mean hospitalization costs were similar between NIPPV ($143,745) and nCPAP ($140,403) from a third-party payer viewpoint.
• Cost-effectiveness analysis indicated a 61% probability that NIPPV is more expensive and less effective than nCPAP.
• Subgroup analysis from a societal perspective yielded similar unfavorable economic results for NIPPV.

Conclusions:

• NIPPV, as utilized in this trial, is not economically favorable compared to nCPAP.
• The findings suggest that nCPAP is the preferred strategy from both clinical and economic standpoints.
• This economic evaluation provides crucial data for healthcare providers and policymakers regarding respiratory support choices for infants.